Myelodysplastic Syndrome — Trials

Myelodysplastic Syndrome — Trials · CancerIndex

Clinical trials

Registered studies

1,702 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 336
Recruiting: 196
Ph III recruiting: 9
Growth YoY: +2.1%
Industry share: 20%
Top sponsor: M.D. Anderson Cancer Center
Termination share: 33.8%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (307)

clinicaltrialsPublishedShowing 1–50 of 103 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT06303193	Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms	recruiting	Phase 1 / Phase 2	160	National Cancer Institute (NCI)NIH	1	Sep 29, 2026	clinicaltrials
NCT05564390	MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)	recruiting	Phase 2	2,000	National Cancer Institute (NCI)NIH